drugset / Trial / NCT05289661
Descemet Endothelial Thickness Comparison Trial I
Phase 3
Active not recruiting
160 enrolled
Stanford University
Case Western Reserve University · collabDartmouth-Hitchcock Medical Center · collabOregon Health and Science University · collabUniversity of California, Davis · collabUniversity of California, San Francisco · collabUniversity of Miami · collabUniversity of Pennsylvania · collabWills Eye Hospital · collab
RandomizedFactorialTriple-blindTreatment
Summary
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.
Timeline
- Start
- 2022-07-15
- Primary completion
- 2026-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ripasudil | Small molecule | 0.4 % | Topical |